Source link : https://www.newshealth.biz/health-news/approval-of-bevacizumab-biosimilar-could-eliminate-access-to-low-cost-amd-therapy/
CHICAGO — Availability of a bevacizumab biosimilar for ophthalmic use could eliminate a lower-cost treatment option for a wide variety of off-label indications and add hundreds of millions of dollars in healthcare costs, according to a study reported here. Bevacizumab-vikg for ophthalmic use has been submitted for FDA approval. A positive decision from the agency […]
Author : News Health
Publish date : 2024-10-24 18:44:08
Copyright for syndicated content belongs to the linked Source.